Denosumab in the treatment of hypercalcemia secondary to malignancy

References

• Stewart AF. Clinical practice. Hypercalcemia associated with malignancy. N Engl J Med. 2005;352(4):373–379.
   PubMed Web of Science ®Google Scholar
• Rosner MH, Dalkin AC. Onco-nephrology: the pathophysiology and treatment of malignancy-associated hypercalcemia. Clin J Am Soc Nephrol. 2012;7(10):1722–1729.
   PubMed Web of Science ®Google Scholar
• Vassilopoulou-Sellin R, Newman BM, Taylor SH, Guinee VF. Incidence of hypercalcemia in patients with malignancy referred to a comprehensive cancer center. Cancer. 1993;71(4):1309–1312.
   Web of Science ®Google Scholar
• Hamilton F, Carroll R, Hamilton W, Salisbury C. The risk of cancer in primary care patients with hypercalcemia: a cohort study using electronic records. Br J Cancer. 2014;111:1410–1412.
   Web of Science ®Google Scholar
• Pelosof LC, Gerber DE. Paraneoplastic syndromes: an approach to diagnosis and treatment. Mayo Clin Proc. 2010;85:838–854.
   PubMed Web of Science ®Google Scholar
• Mazzone PJ, Arroliga AC. Endocrine paraneoplastic syndromes in lung cancer. Curr Opin Pulm Med. 2003;9:313–320.
   PubMed Web of Science ®Google Scholar
• Donovan PJ, Achong N, Griffin K, Galligan J, Pretorius CJ, McLeod DS. PTHrP-mediated hypercalcemia: causes and survival in 138 patients. J Clin Endocrinol Metab. 2015;100(5):2024–2029.
   PubMed Web of Science ®Google Scholar
• Wright JD, Tergas AI, Ananth CV, et al. Quality and outcomes of treatment of hypercalcemia of malignancy. Cancer Invest. 2015;33(8):331–339.
   PubMed Web of Science ®Google Scholar
• Bringhurst D, Demay MB, Kronenberg HM. Hormones and disorders of mineral metabolism. In: Melmed S, Polonsky KS, Larsen PR, Kronenberg HM, editors. Williams Textbook of Endocrinology. 12th ed. St Louis, MO: WB Saunders; 2011:1237–1257.
   Google Scholar
• Lamiere N, Van Biesen W, Vanholder R. Electrolyte disturbances and acute kidney injury in patients with cancer. Semin Nephrol. 2010;30:534–547.
   Google Scholar
• Strewler GJ. The physiology of parathyroid hormone-related protein. N Engl J Med. 2000;342(3):177–185.
   PubMed Web of Science ®Google Scholar
• Horwitz MJ, Tedesco MB, Sereika SM, et al. Continuous PTH and PTHrP infusion causes suppression of bone formation and discordant effects on 1,25(OH)2 vitamin D. J Bone Miner Res. 2005;20(1):1792–1803.
   Google Scholar
• Dean T, Vilardaga JP, Potts JT Jr, Gardella TJ. Altered selectivity of parathyroid hormone (PTH) and PTH-related protein (PTHrP) for distinct conformations of the PTH/PTHrP receptor. Mol Endocrinol. 2008;22(1):156–166.
   PubMed Web of Science ®Google Scholar
• Wysolmerski JJ. Parathyroid hormone-related protein: an update. J Endocrinol Metab. 2012;97(9):2947–2956.
   Google Scholar
• Akhtari M, Mansuri J, Newman KA, Guise TM, Seth P. Biology of breast cancer bone metastasis. Cancer Biol Ther. 2008;7(1):3–9.
   PubMed Web of Science ®Google Scholar
• Sanders JL, Chattopadhyay N, Kifor O, Yamaguchi T, Butters RR, Brown EM. Extracellular calcium-sensing receptor expression and its potential role in regulating parathyroid hormone-related peptide secretion in human breast cancer cell lines. Endocrinology. 2000;141(12):4357–4364.
   PubMed Web of Science ®Google Scholar
• Reagan P, Pani A, Rosner MH. Approach to diagnosis and treatment of hypercalcemia in a patient with malignancy. Am J Kidney Dis. 2013;63(1):141–147.
   Web of Science ®Google Scholar
• Roodman GD. Mechanisms of bone lesions in multiple myeloma and lymphoma. Cancer. 1997;80(Suppl 8):1557–1563.
   Web of Science ®Google Scholar
• VanHouten JN, Yu N, Rimm D, et al. Hypercalcemia of malignancy due to ectopic transactivation of the parathyroid hormone gene. J Clin Endrocrinol Metab. 2006;91(2):580–583.
   Google Scholar
• Seymour JF, Gagel RF. Calcitriol: the major humoral mediator of hypercalcemia in Hodgkin’s disease and non-Hodgkin’s lymphoma. Blood. 1993;82(5):1383–1394.
   PubMed Web of Science ®Google Scholar
• Hewison M, Kantorovich V, Liker HR, et al. Vitamin D-mediated hypercalcemia in lymphoma: evidence for hormone production by tumor-adjacent macrophages. J Bone Miner Res. 2003;18(3):579–582.
   PubMed Web of Science ®Google Scholar
• Toka HR, Al-Romaih, Koshy JM, et al. Deficiency of the calcium-sensing receptor in the kidney cause parathyroid hormone-independent hypocalciuria. J Am Soc Nephrol. 2012;23(11):1879–1890.
   Web of Science ®Google Scholar
• LeGrand SB, Leskuski D, Zama I. Narrative review: furosemide for hypercalcemia: an unproven yet common practice. Ann Intern Med. 2008;149(4):259–263.
   PubMed Web of Science ®Google Scholar
• Cardella CJ, Brikin BL, Rapoport A. Role of dialysis in the treatment of severe hypercalcemia: report of two cases successfully treated with hemodialysis and review of the literature. Clin Nephrol. 1979;12(6):285–290.
   Web of Science ®Google Scholar
• Major P, Lortholary A, Hon J, et al. Zolendronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J Clin Oncol. 2001;19(2):558–567.
   PubMed Web of Science ®Google Scholar
• Nussbaum SR, Younger J, Vanderpol CJ, et al. Single-dose intravenous therapy with pamidronate for the treatment of hypercalcemia of malignancy: comparison of 30-, 60- and 90-mg dosages. Am J Med. 1993;95(3):297–304.
   Web of Science ®Google Scholar
• Ibrahim T, Farolfi A, Mercatali L, Ricci M, Amadori D. Metastatic bone disease in the era of bone-targeted therapy: clinical impact. Tumori. 2013;99(1):1–9.
   Google Scholar
• Dodwell DJ, Howell A, Morton AR, Daley-Yates PT, Hoggarth CR. Infusion rate and pharmacokinetics of intravenous pamidronate in the treatment of tumour-induced hypercalcemia. Postgrad Med J. 1992;68(800):434–439.
   Web of Science ®Google Scholar
• Markowitz GS, Appel GB, Fine PL, et al. Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate. J Am Soc Nephrol. 2001;12(6):1164–1172.
   PubMed Web of Science ®Google Scholar
• Markowitz GS, Fine PL, Stack JI, et al. Toxic acute tubular necrosis following treatment with zolendronate (Zometa). Kidney Int. 2003;64(1):281–289.
   PubMed Web of Science ®Google Scholar
• Vaughn CB, Vaitkevicius VK. The effects of calcitonin in hypercalcemia in patients with malignancy. Cancer. 1974;34(4):1268–1271.
   Google Scholar
• Warrell RP Jr, Bockman RS, Coonley CJ, Isaacs M, Staszewski H. Gallium nitrate inhibits calcium resorption from bone and is effective treatment for cancer-related hypercalcemia. J Clin Invest. 1984;73(5):1487–1490.
   PubMed Web of Science ®Google Scholar
• Devogelaer JP, Lambert M, Boland B, Godfraind C, Noel H, Nagant de Deuxchaisnes C. 1,25-Dihydroxyvitamin D-related hypercalcemia in lymphoma: two case reports. Clin Rheumatol. 1990;9(3):404–410.
   Web of Science ®Google Scholar
• Castellano D, Sepuleda JM, Garcia-Escobar I, Rodriguez-Antolin A, Sundlov A, Cortes-Funes H. The role of RANK-ligand inhibition in cancer: the story of denosumab. Oncologist. 2011;16:136–145.
   PubMed Web of Science ®Google Scholar
• Wada T, Nakashima T, Hiroshi N, et al. RANK-L-RANK signaling in osteoclastogenesis and bone disease. Trends Mol Med. 2006;12:17–25.
   PubMed Web of Science ®Google Scholar
• Eastell R, Christiansen C, Grauer A, et al. Effects of denosumab on bone turnover markers in postmenopausal osteoporosis. J Bone Miner Res. 2011;26(3):530–537.
   PubMed Web of Science ®Google Scholar
• Bone HG, Bolognese MA, Yuen CK, et al. Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. J Clin Endocrinol Metab. 2011;96:972–980.
   PubMed Web of Science ®Google Scholar
• Brown-Glaberman U, Stopeck AT. Role of denosumab in the management of skeletal complications in patients with bone metastases from solid tumors. Biologics. 2012;6:89–99.
   PubMedGoogle Scholar
• Gossai N, Hilgers MV, Polgreen LE, Greegard EG. Critical hypercalcemia following discontinuation of denosumab therapy for metastatic giant cell tumor of bone. Pediatr Blood Cancer. 2015;62:1078–1080.
   PubMed Web of Science ®Google Scholar
• Boyce AM, Chong WH, Yao J, et al. Denosumab treatment for fibrous dysplasia. J Bone Miner Res. 2012;27:1462–1470.
   PubMed Web of Science ®Google Scholar
• Bech A, de Boer H. Denosumab for tumor-induced hypercalcemia complicated by renal failure. Ann Intern Med. 2012;156(12):906–907.
   PubMed Web of Science ®Google Scholar
• Chen C-L, Chen N-C, Liang H-L, et al. Effects of denosumab and calcitriol on severe secondary hyperparathyroidism in dialysis patients with low bone mass. J Clin Endocrinol Metab. 2015;100:2784–2792.
   Web of Science ®Google Scholar
• Cicci JD, Buie L, Bates J, van Deventer H. Denosumab for the management of hypercalcemia of malignancy in patient with multiple myeloma and renal dysfunction. Clin Lymphoma Myeloma Leuk. 2014;14(6):e207–e211.
   PubMedGoogle Scholar
• Cummings SR, San Martin J, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361(8):756–765.
   PubMed Web of Science ®Google Scholar
• Hu MI, Glezerman IG, Leboulleux S, et al. Denosumab for treatment of hypercalcemia of malignancy. J Clin Endocrinol Metab. 2014;99(9):3144–3152.
   PubMed Web of Science ®Google Scholar
• Dietzek A, Connelly K, Cotugno M, Bartel S, McDonnell AM. Denosumab in hypercalcemia of malignancy: a case series. J Oncol Pharm Pract. 2015;21(2):143–147.
   Web of Science ®Google Scholar
• Adhikaree J, Newby Y, Sundar S. RE: denosumab for patients with persistent or relapsed hypercalcemia of malignancy despite recent bisphosphonate treatment. J Natl Cancer Inst. 2015;107(3):509.
   Google Scholar
• Tong CV, Hussein Z, Noor NM, Mohamad M, Ng WF. Use of denosumab in parathyroid carcinoma with refractory hypercalcemia. Q J Med. 2015;108:49–50.
   Google Scholar
• Fountas A, Andrikoula M, Giotaki Z, et al. The emerging role of denosumab in the long-term management of parathyroid carcinoma-related refractory hypercalcemia. Endocr Pract. 2015;21(5):468–473.
   PubMed Web of Science ®Google Scholar
• Karuppiah D, Thanabalasingham G, Shine B, et al. Refractory hypercalcaemia secondary to parathyroid carcinoma: response to high-dose denosumab. Eur J Endocrinol. 2014;171:K1–K5.
   Web of Science ®Google Scholar